[1]Bengel F M, Takahiro H, Javadi M S, et al. Cardiacpositron emission tomography[J]. Journal of the American College of Cardiology, 2009, 54(1): 1-15.
[2]Zhao Z, Liu M, Fang W, et al. Sulfonyl-containing boronate caps for optimization of biological properties of 99mTc(Ⅲ) radiotracers-[99mTcCl(CDO)(CDOH)2BR] (CDOH2 = cyclohexanedione dioxime)[J]. J Med Chem, 2018, 61(1): 319-328.
[3]Xi X Y, Wang L, Hsu B L, et al. 99mTc-3SPboroxime: a neutral 99mTc(Ⅲ) radiotracer with high heart uptake and long myocardial retention[J]. J Nuc Cardiol, 2021, 28(6): 2687-2696.
[4]Di Carli M F, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease[J]. Circulation, 2007, 115(11): 1464-1480.
[5]Baggish A L, Boucher C A. Radiopharmaceutical agents for myocardial perfusion imaging[J]. Circulation, 2008, 118(16): 1668-1674.
[6]Henneman M M, Schuijf J D, van der Wall E E, et al. Non-invasive anatomical and functional imaging for the detection of coronary artery disease[J]. Br Med Bull, 2006, 79-80(1): 187-202.
[7]Klein R, Hung G U, Wu T C, et al. Feasibility and operator variability of myocardial blood flow and reserve measurements with 99mTc-sestamibi-quantitative dynamic SPECT/CT imaging[J]. J Nucl Cardiol, 2014, 21(6): 1075-1088.
[8]Nekolla S G, Rischpler C, Nakajima K. Myocardial blood flow quantification with SPECT and conventional tracers: a critical appraisal[J]. J Nucl Cardiol, 2014, 21(6): 1089-1091.
[9]Sogbein O O, Pelletier-Galarneau M, Schindler T H, et al. New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease[J]. Biomed Res Int, 2014: 942-960.
[10]Liu M, Zheng Y, Avcibasi U, et al. Novel 99mTc(Ⅲ)-azide complexes [99mTc(N3)(CDO)(CDOH)2B-R] (CDOH2=cyclohexanedione dioxime) as potential radiotracers for heart Imaging[J]. Nucl Med Biol, 2016, 43(11): 732-741.
[11]Slomka P J, Berman D S, Germano G. Absolute myocardial blood flow quantification with SPECT/CT: is it possible?[J]. J Nucl Cardiol, 2014, 21(6): 1092-1095.
[12]Dahlberg S T, Gilmore M P, Leppo J A. Interaction of technetium 99m-labeled teboroxime with red blood cells reduces the compound’s extraction and increases apparent cardiac washout[J]. J Nucl Cardiol, 1994, 1(3): 270-279.
[13]Marshall R C, Leidholdt E M J, Zhang D Y, et al. The effect of flow on technetium-99m-teboroxime (SQ30217) and thallium-201 extraction and retention in rabbit heart[J]. J Nucl Med, 1991, 32(10): 1979-1988.
[14]Agostini D, Roule V, Nganoa C, et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study[J]. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1079-1090.
[15]Beanlands R, Muzik O, Nguyen N, et al. The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow[J]. J Am Coll Cardiol, 1992, 20(3): 712-719.
[16]Smith A M, Gullberg G T, Christian P E. Experimental verification of technetium 99m-labeled teboroxime kinetic parameters in the myocardium with dynamic single-photon emission computed tomography: reproducibility, correlation to flow, and susceptibility to extravascular contamination[J]. J Nucl Cardiol, 1996, 3(2): 130-142.
[17]Rumsey W L, Rosenspire K C, Nunn A D. Myocardial extraction of teboroxime: effects of teboroxime interaction with blood[J]. J Nucl Med, 1992, 33(1): 94-101.
[18]Smith A M, Gullberg G T, Christian P E. Experimental verification of technetium 99m-labeled teboroxime kinetic parameters in the myocardium with dynamic single-photon emission computed tomography: reproducibility, correlation to flow, and susceptibility to extravascular contamination[J]. J Nucl Cardiol, 1996, 3(2): 130-142.
[19]Schindler T H. Positron-emitting myocardial blood flow tracers and clinical potential[J]. Prog Cardiovasc Dis, 2015, 57(6): 588-606.
[20]Berman D S, Maddahi J, Tamarappoo B K, et al. Phase Ⅱ safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F-18 positron emission tomography[J]. J Am Coll Cardiol, 2013, 61(4): 469-477.
|